Biomerica, Inc. (BMRA) to Post FY2019 Earnings of ($0.25) Per Share, B. Riley Forecasts

Share on StockTwits

Biomerica, Inc. (NASDAQ:BMRA) – Equities research analysts at B. Riley raised their FY2019 earnings estimates for shares of Biomerica in a research note issued on Tuesday, September 4th. B. Riley analyst A. D’silva now forecasts that the company will post earnings of ($0.25) per share for the year, up from their previous estimate of ($0.28). B. Riley also issued estimates for Biomerica’s FY2020 earnings at ($0.27) EPS, FY2021 earnings at ($0.04) EPS and FY2022 earnings at $0.84 EPS.

BMRA stock opened at $3.59 on Friday. Biomerica has a 1 year low of $2.68 and a 1 year high of $9.32. The stock has a market capitalization of $31.88 million, a P/E ratio of -21.09 and a beta of -0.66.

Biomerica (NASDAQ:BMRA) last issued its quarterly earnings data on Thursday, August 30th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.02). Biomerica had a negative net margin of 19.46% and a negative return on equity of 27.29%. The firm had revenue of $1.13 million for the quarter, compared to the consensus estimate of $1.53 million.

About Biomerica

Biomerica, Inc, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; and to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations.

Read More: Dividend

Earnings History and Estimates for Biomerica (NASDAQ:BMRA)

Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with's FREE daily email newsletter.

Leave a Reply